

Please try another search
For the three months ended 31 March 2022, Unicycive Therapeutics Inc revenues was not reported. Net loss increased from $964K to $3.5M. Higher net loss reflects Research and development - Balancing v increase from $266K to $1.8M (expense), General and administrative - Balancing increase from $263K to $1.4M (expense), Stock-based Compensation in SGA increase from $18K to $191K (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -3.54 | -2.75 | -4.71 | -0.78 |
Net Income | -3.54 | -2.75 | -5.2 | -1.1 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 15.76 | 18.74 | 19.78 | 0.91 |
Total Liabilities | 2.52 | 2.26 | 0.79 | 5.12 |
Total Equity | 13.24 | 16.48 | 19 | -4.2 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -2.96 | -5.77 | -4.36 | -0.89 |
Cash From Investing Activities | -0 | -0.03 | ||
Cash From Financing Activities | 0 | 22.38 | 22.38 | 0.89 |
Net Change in Cash | -2.96 | 16.58 | 18.01 | 0 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review